Observational studyFrontiers in immunology2025
Pilot proteomic analysis of immune dysregulation in dengue with prior SARS-CoV-2 infection.
Observational study in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Proteomic signals are not equal clinical phenotypes: redefining evidence standards in arbovirus-SARS-CoV-2 cross-reactivity.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In regions where dengue and COVID-19 co-circulate, cross-reactive antibodies elicited by SARS-CoV-2 may exacerbate dengue severity. This exploratory, cross-sectional, observational pilot study evaluated whether prior SARS-CoV-2 exposure modulated dengue pathogenesis through proteomic profiling and Methods: Eighteen participants from Oaxaca, Mexico, were prospectively stratified into four cohorts: healthy controls (CG), dengue with anti-SARS-CoV-2 IgG (NS1/SARS_IgG), dengue with both anti-SARS-CoV-2 and anti-dengue IgG (NS1/SARS-DENV_IgG), and dengue with anti-dengue IgG only (NS1/DENV_IgG). The serum levels of IL-6 and C-reactive protein (CRP) were quantified, and proteomic analysis was performed using label-free Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). Results: The NS1/DENV_IgG group exhibited the most severe clinical presentation, including 39 °C fever and 50% thrombocytopenia. In contrast, the NS1/SARS-DENV_IgG group presented milder symptoms. IL-6 and CRP concentrations peaked in the NS1/SARS_IgG group (18.3 ± 15.6 pg/mL and 51.6 ± 29.6 mg/L, respectively). Proteomic profiling identified 279 high-confidence proteins and 18 differentially expressed proteins (DEPs). The NS1/SARS-DENV_IgG group showed enrichment in the complement/coagulation pathways (p = 0.016) and TGF-β signaling (p = 0.022). DEPs, including thrombospondin-1 and PRG2, have been implicated in Th2 polarization and ADE-like immune dysregulation. ADE assays confirmed that anti-SARS-CoV-2 serum enhanced DENV replication Conclusions: Prior SARS-CoV-2 exposure may potentiate dengue severity via cross-reactive antibody-mediated immune modulation, skewing toward Th2 responses and enhancing viral replication. These findings suggest novel candidate biomarkers for stratifying the dengue risk in co-endemic regions. However, the study's exploratory nature, small cohort (n = 18), pooled proteomic methodology, and limited clinical characterization necessitate validation in larger longitudinal studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.